Cargando…

Drug Delivery Technology Development in Canada

Canada has a long and rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasan, Kishor M., Badea, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835823/
https://www.ncbi.nlm.nih.gov/pubmed/31627471
http://dx.doi.org/10.3390/pharmaceutics11100541
_version_ 1783466763875254272
author Wasan, Kishor M.
Badea, Ildiko
author_facet Wasan, Kishor M.
Badea, Ildiko
author_sort Wasan, Kishor M.
collection PubMed
description Canada has a long and rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve rational site-targeting, or facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of the presence of the drug in the body. Drug delivery is often approached through a drug’s chemical formulation, medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form development and selection of route of administration; the latter sometimes even being considered part of the definition. Drug delivery technologies modify drug release profile, absorption, distribution and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and adherence. Over the past 30 years, numerous Canadian-based biotechnology companies have been formed stemming from the inventions conceived and developed within academic institutions. Many have led to the development of important drug delivery products that have enhanced the landscape of drug therapy in the treatment of cancer to infectious diseases. This Special Issue serves to highlight the progress of drug delivery within Canada. We invited articles on all aspects of drug delivery sciences from pre-clinical formulation development to human clinical trials that bring to light the world-class research currently undertaken in Canada for this Special Issue.
format Online
Article
Text
id pubmed-6835823
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68358232019-11-25 Drug Delivery Technology Development in Canada Wasan, Kishor M. Badea, Ildiko Pharmaceutics Editorial Canada has a long and rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve rational site-targeting, or facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of the presence of the drug in the body. Drug delivery is often approached through a drug’s chemical formulation, medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form development and selection of route of administration; the latter sometimes even being considered part of the definition. Drug delivery technologies modify drug release profile, absorption, distribution and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and adherence. Over the past 30 years, numerous Canadian-based biotechnology companies have been formed stemming from the inventions conceived and developed within academic institutions. Many have led to the development of important drug delivery products that have enhanced the landscape of drug therapy in the treatment of cancer to infectious diseases. This Special Issue serves to highlight the progress of drug delivery within Canada. We invited articles on all aspects of drug delivery sciences from pre-clinical formulation development to human clinical trials that bring to light the world-class research currently undertaken in Canada for this Special Issue. MDPI 2019-10-17 /pmc/articles/PMC6835823/ /pubmed/31627471 http://dx.doi.org/10.3390/pharmaceutics11100541 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Wasan, Kishor M.
Badea, Ildiko
Drug Delivery Technology Development in Canada
title Drug Delivery Technology Development in Canada
title_full Drug Delivery Technology Development in Canada
title_fullStr Drug Delivery Technology Development in Canada
title_full_unstemmed Drug Delivery Technology Development in Canada
title_short Drug Delivery Technology Development in Canada
title_sort drug delivery technology development in canada
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835823/
https://www.ncbi.nlm.nih.gov/pubmed/31627471
http://dx.doi.org/10.3390/pharmaceutics11100541
work_keys_str_mv AT wasankishorm drugdeliverytechnologydevelopmentincanada
AT badeaildiko drugdeliverytechnologydevelopmentincanada